Acute kidney injury in non-intensive care unit and intensive care unit patients treated with vancomycin and piperacillin-tazobactam.
We investigated the incidence of acute kidney injury (AKI) and the risk factors associated with vancomycin (VAN) and piperacillin-tazobactam (TZP) combination therapy in non-intensive care unit (ICU) and ICU settings. In this single-center retrospective cohort study, adult patients who received VAN for ≥ 48 h between 1 January 2016 and 31 December 2017 were included. The primary end point was the incidence of AKI. A total of 593 adult patients were included. The incidence of AKI was 10.6% overall, 8.0% in the non-TZP group, and 19.8% in the TZP group. In a univariate analysis, the odds of AKI were higher in the TZP group than in the non-TZP group (odds ratio (OR) = 2.84, 95% confidence interval (CI) = 1.64-4.90). In both non-ICU and ICU settings, the odds of AKI were higher in the TZP group than in the non-TZP group (non-ICU: OR = 3.04, 95% CI = 1.52-6.09; ICU: OR = 2.51, 95% CI = 1.03-6.08). Furthermore, a propensity score analysis revealed that the odds of AKI were higher in the TZP group than in the non-TZP group (OR = 2.81, 95% CI = 1.52-5.17). In both non-ICU and ICU settings, the odds of AKI were higher in the TZP group than in the non-TZP group (non-ICU: OR = 2.57, 95% CI = 1.17-5.64; ICU: OR = 3.51, 95% CI = 1.05-11.6). The combined use of TZP in patients receiving VAN increased the incidence of AKI in both non-ICU and ICU settings.